Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of November 2020, with the report dated November 25, 2020. The document serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of an insider transaction.
| Instrument | Transaction Type | Price | Volume |
|---|---|---|---|
| American Depositary Shares (ADSs) | Acquisition (Executive Supplemental Savings Plan) | $36.7400 | 1,134.3152 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single acquisition event by Dr. H Barron, Chief Scientific Officer and President, R&D, on November 23, 2020, executed on the New York Stock Exchange.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory compliance notification for a specific executive transaction.
Key Facts for Investor Verification
- Insider Activity: Dr. H Barron acquired 1,134.3152 ADSs at $36.74 per share.
- Transaction Context: The purchase was made within the GSK Executive Supplemental Savings Plan account.
- Timing: The transaction occurred on November 23, 2020, two days prior to the filing date.
- Financial Data: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F or other earnings releases for performance metrics.